We previously demonstrated that latent HBV infection is accompanied by ongoing viral replication in the liver but not in the serum or lymphatic cells of healthy anti-HBcpositive liver transplant donors [3, 4] . It is possible for latently infected HBV to be transmitted from anti-HBcpositive donors to recipients via liver grafts and reactivated under the immunosuppressive conditions imposed after liver transplantation. This reactivation is called de novo activation of HBV [5] [6] [7] .
Most individuals who are negative for hepatitis B surface antigen (HBsAg) but positive for hepatitis B core antibody (anti-HBc) -which is indicative of resolved hepatitis B -have persistent viral infection in the liver [1, 2] . We previously demonstrated that latent HBV infection is accompanied by ongoing viral replication in the liver but not in the serum or lymphatic cells of healthy anti-HBcpositive liver transplant donors [3, 4] . It is possible for latently infected HBV to be transmitted from anti-HBcpositive donors to recipients via liver grafts and reactivated under the immunosuppressive conditions imposed after liver transplantation. This reactivation is called de novo activation of HBV [5] [6] [7] .
To prevent de novo activation of HBV after liver transplantation, hepatitis B immunoglobulin (HBIG) had been widely used as a prophylaxis post-surgery [7] [8] [9] , although lamivudine with or without HBIG has recently become the standard prophylaxis [10, 11] . Even under HBIG prophylaxis, occurrence of de novo activation of HBV has been reported [8, 12, 13] . Recently, we reported that de novo hepatitis B occurred in 24% of HBV-naive recipients who received liver grafts from anti-HBc-positive donors [13] . Among these cases, one of the most important factors associated with HBV activation was found to be the emergence of HBV with escape mutations from hepatitis B surface antibody (anti-HBs). Escape mutations from anti-HBs occur in the common 'a' determinant region of the surface gene, which is a highly conformational region of the HBsAg protein.
Mutations in and around the 'a' determinant region have been shown to alter the antigenicity of the HBsAg protein; consequently, anti-HBs fails to neutralize HBV Introduction [14] [15] [16] . Anti-HBs escape mutations have been found in patients vaccinated for HBV [17, 18] , in patients with chronic hepatitis B [19, 20] and in liver transplant recipients after HBIG administration [21, 22] . The clinical significance of the anti-HBs escape mutant HBV has been well-analysed in patients after HBV vaccination. The prevalence of anti-HBs escape mutants after HBV vaccination was reported to have increased from 7.8% in 1984 to 19.6% in 1989; after a 1994 survey, prevalence was reported to be 28.1% [18] . Commonly reported mutations in HBsAg with the potential to escape neutralization by vaccine-induced antibody in patients after HBV vaccination include G145R, D144A, P142S, K141E, Q129H, I/T126N/A and M133L [18, 23] . By contrast, the clinical features of anti-HBs escape mutants after liver transplantation under HBIG prophylaxis have not been well-analysed. Treatment strategies for HBV with anti-HBs escape mutations have not been clarified. At present, several nucleoside analogues such as lamivudine, adefovir and entecavir are available for the treatment of chronic hepatitis B [24] . Among them, entecavir, a carbocyclic analogue of 2′-deoxyguanosine, has been shown to have higher efficacy and lower rates of resistance than lamivudine for patients with chronic hepatitis B [24] ; therefore, entecavir is now used as a first-line therapy in the treatment of chronic hepatitis B worldwide. However, the efficacy of nucleoside analogues for HBV with escape mutations from anti-HBs is unknown.
Original article
The aim of this study was to clarify the clinical features of de novo activation of HBV with escape mutations from anti-HBs under HBIG prophylaxis after liver transplantation.
Methods

Patients
We retrospectively analysed the medical records of 157 patients who underwent living donor liver transplantation (LDLT) using liver grafts from HBsAg-negative but anti-HBc-positive donors from July 1995 to August 2008 ( Figure 1A ). Of these, 57 recipients were excluded from our study because their sera were pre-operatively positive for HBsAg and/or HBV DNA. An additional 25 patients were also excluded from the study because of the short duration (<6 months) of their follow-up in our hospital. Accordingly, 75 patients with a follow-up period of >6 months were enrolled in this study. The study protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (Kyoto, Japan), and all patients provided informed consent.
Prophylaxis with HBIG and immunosuppressive protocol
HBIG monotherapy was given to all recipients with grafts from anti-HBc-positive donors, as reported previously [7] . The first application of HBIG at a dose of 200 IU/kg body mass was administered during the anhepatic phase of LDLT, and 100 IU/kg of HBIG was administered, if required, to maintain serum anti-HBs titres at >500 IU/l during the first post-operative month. Subsequently, HBV serological markers were examined at monthly intervals after the transplant operation, and 1,000 IU of HBIG was periodically administered to maintain serum anti-HBs titres at >200 IU/l throughout the follow-up period.
The standard immunosuppression protocol comprised tacrolimus and low-dose steroid therapy. The target whole blood lower level for tacrolimus was 10-15 ng/ml during the first 2 weeks, 10 ng/ml thereafter and 5-8 ng/ml starting from the second month. Steroid therapy was initiated at a dose of 10 mg/kg of prednisolone before graft reperfusion, then tapered down from 1 mg/kg per day on the first day to 0.3 mg/ kg per day until the end of the first month, followed by 0.1 mg/kg per day until the end of the third month. After that, steroid administration was terminated.
Diagnosis of de novo activation of HBV
De novo activation of HBV was diagnosed when HBsAg and HBV DNA became positive in the serum of the liver transplant recipient. Serological HBV markers, including HBsAg, anti-HBs, anti-HBc, hepatitis B e antigen (HBeAg) and antibodies to HBeAg (anti-HBe), were measured by chemiluminescent enzyme immunoassay (CLEIA; Fuji Rebio, Tokyo, Japan). Serum HBV DNA titre was analysed using a commercial PCR assay (Amplicor HBV Monitor; Roche, Branchburg, NJ, USA).
PCR amplification of HBV DNA and sequencing of the surface gene Serum samples were obtained at the diagnosis of de novo activation of HBV for the analysis of HBV DNA sequencing. Preparation of DNA samples and detection of HBV genomes by PCR have been described previously [3, 13] . The nucleotide sequence spanning the S region was amplified by PCR using specific primers, 5′-TGCCCTTGGATAAAGGCATT-3′ and 5′-AAGTTAAGGGAGTAGCCCCA-3′, followed by direct sequencing analyses using primers 5′-CCTGCTGGTGGCTCCAGTTC-3′ and 5′-AAGTTAAGGGAGTAGCCCCA-3′.
Statistical analysis
Baseline characteristics were tabulated and compared between patients with activation of HBV with anti-HBs escape mutations and patients without HBV activation (Table 1) . For continuous variables, medians and ranges are given, and the data were analysed by the Wilcoxon rank-sum test. For categorical variables, counts are given, and the data were analysed by the χ 2 test. The rates of patients who showed HBV activation after LDLT were estimated using the Kaplan-Meier method. P<0.05 was considered significant.
Results
De novo activation of HBV in recipients from antiHBc-positive donors
Among the 75 recipients who received HBIG prophylaxis >6 months after LDLT with liver grafts from anti-HBcpositive donors, 19 (25%) patients developed de novo activation of HBV ( Figure 1A ). The rate of HBV activation estimated by the Kaplan-Meier method was 3% at 1 year, 17% at 3 years, 25% at 5 years, and 29% at 10 years ( Figure 1B ). Of the 19 recipients with HBV activation, 8 had HBV activation due to transient discontinuation of HBIG ( Figure 1A ). In the remaining 11 patients with HBV activation, despite continuous HBIG prophylaxis, the emergence of HBV with anti-HBs escape mutations was confirmed in 7 patients, including 2 patients who were described in our previous report [13] . The rate of de novo activation of HBV with anti-HBs escape mutations estimated by the Kaplan-Meier method was 8% at 3 years and 12% at 5 years ( Figure 1B ). The other four recipients, in whom the reason for HBV activation was unknown, were previously reported by us [13] .
Clinical features of patients with de novo activation of HBV with anti-HBs escape mutations
To clarify the characteristics of patients with de novo activation of HBV with anti-HBs-escape mutations, the clinical features of recipients with HBV with antiHBs escape mutations (n=7) were listed and compared HBsAg-positive recipients n=57
Follow-up <6 months n=25
HBIG prophylaxis >6 months n=75
Continuous HBIG prophylaxis n=11
Discontinuation of HBIG n=8
No HBV activation n=56
HBV activation n=19
Anti-HBs escape mutation n=7
Unknown n=4
Reason for HBV activation with those of recipients without HBV activation (n=56; Table 1 ). The two groups of patients did not differ significantly by age, sex or serological markers for HBV before LDLT with regard to either recipients or donors. Of note, all seven patients with de novo activation of HBV with anti-HBs escape mutations were negative for anti-HBc pre-operatively, and no anti-HBc-positive recipients (n=17) developed de novo activation of HBV. The details of the clinical features of the seven patients who developed de novo activation of HBV with anti-HBs-escape mutations are summarized in Table 2 . In the seven patients, serum HBsAg and HBV DNA became positive 15.7-54.9 months (median 24.1 months) after LDLT. Serum anti-HBs titres were maintained at 27.8-418.4 IU/l before HBV activation by HBIG administration. At the time of HBV activation, all patients were positive for anti-HBs, despite being positive for serum HBV DNA and HBsAg, when de novo hepatitis B was diagnosed. The genotype of HBV in all seven patients was C, which is the major genotype in Japan [25] . All patients showed high serum ALT levels. Five of the seven patients received tacrolimus only for immunosuppression at the time of HBV activation, patient number 3 had tacrolimus with prednisolone and mycophenolate mofetil, and patient number 4 received cyclosporine and prednisolone.
Sequence analysis of serum HBV DNA
Results of the sequence analysis of serum HBV DNA in these seven patients are shown in Figure 2 . We focused our analysis on the immunodominant loop encompassing amino acid (aa) 101-163 of the S protein, which includes the 'a' determinant region (aa 124-147), the major target of neutralizing antiHBs antibodies due to its exposure at the surface of viral particles [14, 16, 26] . Sequencing of the S gene revealed the presence of mutations in the immunodominant loop in all patients. These mutations within the S protein led to G145A substitution in patient number 1, G145R substitution in patients numbered 2, 3, 4, 6 and 7, and Q129P substitution in patient number 5 ( Figure 2B ). 
Treatment for de novo activation of HBV with anti-HBs escape mutations
Entecavir treatment (0.5 mg) was started for four patients (numbers 1-4) immediately after the diagnosis of de novo activation of HBV with anti-HBs-escape mutations. After the administration of entecavir, serum HBsAg and HBV DNA promptly decreased and became undetectable at 2.5, 3.3, 6 and 2.5 months after the start of entecavir treatment, respectively ( Figure 3 and Table 3 ). Serum ALT levels also decreased in association with the decrease in serum HBV DNA. After confirming the stable negativity of HBsAg, entecavir treatment was stopped in three patients (numbers 1-3) at 5.8, 5.9 and 9.9 months after beginning the treatment, respectively. Thereafter, serum HBsAg and HBV DNA remained negative during the follow-up periods of 22.2, 24.7 and 20.6 months after withdrawal of entecavir, respectively (Table 3) . Entecavir administration was continued for patient number 4 at the time of the analysis for this study because the patient wanted to continue the treatment. Patients numbered 5 and 6 received early administration of lamivudine after the diagnosis of de novo activation of HBV. However, they did not achieve serum HBV clearance by 26.6 and 4.6 months, respectively, at which time adefovir was added. Even after treatment with a combination of lamivudine and adefovir for 33.2 months, patient number 5 remained chronically HBsAgpositive. In patient number 6, serum HBsAg and HBV DNA became negative at 9.5 months after adefovir administration. Patient number 7 who did not receive nucleoside analogue treatment for hepatitis B developed chronic hepatitis B as confirmed by liver histology.
Discussion
In this report, we demonstrated the clinical features of de novo activation of HBV with anti-HBs-escape mutations under HBIG prophylaxis after liver transplantation. The rate of de novo activation of HBV with anti-HBs escape mutations was 12% at 5 years. No significant difference of baseline characteristics between patients with de novo activation of HBV with anti-HBsescape mutations and patients without HBV activation was identified, but all patients who had activation of anti-HBs escape mutant HBV were pre-operatively anti-HBc-negative. Early entecavir treatment was very effective for patients with de novo activation of HBV with anti-HBs escape mutations and the treatment induced complete clearance of serum HBsAg and HBV DNA and resulted in sustained negativity for HBsAg even after the termination of entecavir treatment. Two reasons for de novo activation of HBV after LDLT from anti-HBc-positive donors were revealed in this study: discontinuation of HBIG and emergence of an anti-HBs escape mutant. However, the reason for de novo HBV activation in four patients is still unknown. HBV activation by HBIG discontinuation is preventable by careful follow-up to reduce non-compliance of HBIG use. The most important reason for HBV activation is emergence of anti-HBs escape mutations under HBIG prophylaxis, because it is unpredictable and difficult to prevent. In the present study, no antiHBc-positive patients developed de novo activation of HBV with anti-HBs-escape mutations. The reason for this is also unknown, but we expect that individuals with resolved hepatitis B have memory T-cells and various antibodies for HBV, including antibodies against PreS1 and PreS2 as well as anti-HBs, and the T-cells and antibodies could inhibit the proliferation of HBV with anti-HBs-escape mutations.
A characteristic serological feature at the onset of de novo activation of HBV with anti-HBs-escape mutations was positivity of anti-HBs at the time of HBV DNA appearance in the serum. Because antiHBs cannot bind HBsAg that has anti-HBs escape mutations [16] , HBV will increase even in the presence of anti-HBs. Therefore, we must be cautious to the development of hepatitis B due to HBV with antiHBs-escape mutations, even when serum anti-HBs titre is maintained at a high level by HBIG administration. A regular evaluation of serum HBsAg and/ or HBV DNA is recommended. Duration from liver transplantation to activation of anti-HBs-escape mutants were 15.7-54.9 months in this study. The previous study reported that activation of HBV with anti-HBs-escape mutations in HBsAg-positive recipients occurred 1-20 months after liver transplantation [22] . According to these results, the regular evaluation of HBV should be initiated just after liver transplantation and continued for the patient's lifetime.
The natural clinical course after de novo activation of HBV without nucleoside analogue treatment has been revealed in previous reports. We reported on a total of 19 cases of de novo activation of HBV after LDLT [7, 13] without treatment after HBV activation. Overall, 16 of the 19 (84%) recipients, including 1 patient with anti-HBs escape mutant HBV, became HBsAg carriers; 1 died of fibrosing cholestatic hepatitis and only 2 patients spontaneously resolved to an HBsAg-negative state. Similar results showing that a majority of patients suffering from de novo activation of HBV after liver transplantation developed liver cirrhosis or chronic hepatitis have been reported [5, 6, 27] . These results indicate that most patients with de novo activation of HBV after liver transplantation enter an HBsAg carrier state without anti-HBV treatment because of the immunosuppressive conditions. Therefore, an effective management strategy is required for patients with de novo activation of HBV after liver transplantation.
We recently reported the beneficial effects of shortterm lamivudine treatment for de novo activation of HBV caused by reasons other than anti-HBs escape mutations [13] . Lamivudine administration during the acute phase of de novo activation of HBV resulted in complete clearance of HBsAg from the serum in five of six patients, and all five remained negative for HBsAg even after the termination of lamivudine treatment. However, as shown in the present study, clearance of HBsAg was not achieved in two patients with HBV with anti-HBs escape mutation by lamivudine administration. Although one patient achieved clearance of HBsAg after administration of adefovir, another patient developed chronic hepatitis B despite adding adefovir. In contrast, we demonstrated here the potent efficacy of entecavir on HBV with anti-HBs-escape mutations. The reason for the difference in efficacy between lamivudine and entecavir is unclear. Recent reports indicate that the overlap of the gene encoding HBsAg by the polymerase gene creates a unique situation in which a change within the polymerase gene following nucleoside analogue treatment might result in structural changes in the HBsAg protein and a subsequent reduction in the antigenicity of the protein. Lamivudine-resistant mutations in the polymerase gene are, indeed, associated with changes in the HBsAg protein, with a consequent reduction in antigenicity of the HBsAg protein comparable to that of anti-HBs-escape mutants [28, 29] . The reverse might also be true. It has been reported that anti-HBs-escape mutations can produce a functionally significant alteration in the viral polymerase and influence the viral replication phenotype [30] . Both entecavir and lamivudine are nucleoside analogues that inhibit the HBV polymerase, but the mechanism of inhibition is different between these two nucleoside analogues. Entecavir inhibits HBV replication at three different steps: the priming of HBV DNA polymerase, reverse transcription of the negative-strand HBV DNA from the pregenomic RNA, and synthesis of the positivestrand HBV DNA, whereas lamivudine lacks the effect of the priming of HBV DNA polymerase [31] . The difference in the mechanism of HBV polymerase inhibition between entecavir and lamivudine may contribute to the difference in the efficacy of each nucleoside analogue on HBV with anti-HBs-escape mutations.
In conclusion, escape mutations from anti-HBs caused de novo activation of HBV under HBIG prophylaxis after liver transplantation from donors with resolved hepatitis B. Early administration of entecavir is important to avoid the subsequent development of acute liver failure or chronic hepatitis caused by de novo activation of HBV with anti-HBsescape mutants. Table 3 . Treatment for seven patients with de novo activation of HBV with anti-HBs escape mutation after liver transplantation Anti-HBs, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; NA, nucleoside analogue.
